Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2015 Oct 27;6(33):34300-8.
doi: 10.18632/oncotarget.5549.

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Rui Wang  1   2 , Yang Zhang  1   2 , Yunjian Pan  1   2 , Yuan Li  2   3 , Haichuan Hu  1   2 , Deng Cai  1   2 , Hang Li  1   2 , Ting Ye  1   2 , Xiaoyang Luo  1   2 , Yiliang Zhang  1   2 , Bin Li  1   2 , Lei Shen  2   3 , Yihua Sun  1   2 , Haiquan Chen  1   2   4   5
Affiliations

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Rui Wang et al. Oncotarget. .

Abstract

Purpose: To determine the frequency of driver mutations in Chinese non-small cell lung cancer (NSCLC) patients. VSports手机版.

Methods: Comprehensive mutational analysis was performed in 1356 lung adenocarcinoma, 503 squamous cell carcinoma, 57 adenosquamous lung carcinoma, 19 large cell carcinoma and 8 sarcomatoid carcinoma. The effect of EGFR tyrosine kinase inhibitors (TKIs) on EGFR-mutated lung adenocarcinoma patients after disease recurrence was investigated. V体育安卓版.

Results: Mutations in EGFR kinase domain, HER2 kinase domain, KRAS, BRAF, ALK, ROS1 and RET were mutually exclusive. In lung adenocarcinoma cases "pan-negative" for the seven above-mentioned driver mutations, we also detected two oncogenic EGFR extracellular domain mutations (A289D and R324L), two HER2 extracellular and transmembrane domain mutations (S310Y and V659E), one ARAF S214C mutation and two CD74-NRG1 fusions. Six (1. 2%) FGFR3 activating mutations were identified in lung squamous cell carcinoma (five S249C and one R248C). There were three (15. 8%) EGFR mutations and four (21. 1%) KRAS mutations in large cell carcinoma. Three (37. 5%) KRAS mutations were detected in sarcomatoid carcinoma. In EGFR-mutated lung adenocarcinoma patients who experienced disease recurrence, treatment with EGFR TKIs was an independent predictor of better overall survival (HR = 0. 299, 95% CI: 0. 172-0. 519, P < 0. 001) V体育ios版. .

Conclusion: We determined the frequency of driver mutations in a large series of Chinese NSCLC patients. EGFR TKIs might improve the survival outcomes of EGFR-mutated lung adenocarcinoma patients who experienced disease recurrence VSports最新版本. .

Keywords: ERBB; FGFR; driver mutations; non-small cell lung cancer V体育平台登录. .

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

There are no conflicts of interest to disclose.

Figures

Figure 1
Figure 1. Frequency of driver mutations in lung adenocarcinoma
A. and lung adenocarcinoma “pan-negative” for mutations in EGFR kinase domain, KRAS, HER2 kinase domain, BRAF, ALK, ROS1 and RET B.
Figure 2
Figure 2. Frequency of driver mutations in lung squamous cell carcinoma
A. adenosquamous carcinoma B. large cell carcinoma C. and sarcomatoid carcinoma D.
Figure 3
Figure 3. Recurrence-free survival
A. and overall survival B. according to FGFR fusion and mutation status. FGFR (+), either FGFR fusion or FGFR mutation was positive; FGFR (−), both FGFR fusion and FGFR mutation were negative.
Figure 4
Figure 4. Overall survival of EGFR-mutated lung adenocarcinoma patients with or without the treatment of EGFR tyrosine kinase inhibitors (TKI) after disease recurrence
A. all patients; B. stage I-II patients; C. stage III patients.
See this image and copyright information in PMC

References

    1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. - PubMed
    1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128. - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388. - PubMed

Publication types

MeSH terms